ArticleInternal medicine (Tokyo, Japan)2026
Microscopic Polyangiitis with Alveolar Hemorrhage Complicated by Myasthenia Gravis.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes the case of an 80-year-old man with ocular myasthenia gravis, who developed microscopic polyangiitis with alveolar hemorrhage. This rare co-occurrence of the two autoimmune diseases presented significant diagnostic and therapeutic challenges. Despite the initial improvement with glucocorticoids, the patient relapsed and died before receiving additional immunosuppressive agents. Thus, the balance between therapeutic efficacy and adverse effects, such as infections, must be carefully considered, especially in elderly patients. This case underscores the importance of recognizing rare overlaps of autoimmune diseases and highlights the need for individualized treatment strategies, especially in older individuals, in whom aggressive immunosuppression carries additional risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.